Just read the report. Impressive clinical trials results.
Key Highlights:
• Travelan® shigellosis challenge studies in non-human primates successfully completed
• Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treatedanimals compared to placebo and demonstrated a significant clinical benefit
• Prophylactic administration of Travelan® may provide an effective prevention alternative toantibiotics for gastrointestinal infections in humans
• Three new Shigella specific anti-microbial therapeutics under preclinical evaluation
• A preventative treatment that protects against enteric diseases, specifically Shigella, is a highpriority objective for the US Army
- Forums
- ASX - By Stock
- IMC
- Ann: US DoD Reports Results from Travelan Shigellosis Study
Ann: US DoD Reports Results from Travelan Shigellosis Study, page-2
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMC (ASX) to my watchlist
|
|||||
Last
9.8¢ |
Change
0.001(1.03%) |
Mkt cap ! $22.34M |
Open | High | Low | Value | Volume |
9.8¢ | 9.8¢ | 9.8¢ | $3.639K | 37.13K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2306 | 9.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.9¢ | 28455 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2306 | 0.097 |
2 | 21199 | 0.095 |
1 | 22432 | 0.094 |
1 | 40000 | 0.093 |
1 | 80000 | 0.091 |
Price($) | Vol. | No. |
---|---|---|
0.099 | 28455 | 3 |
0.100 | 171349 | 4 |
0.105 | 108309 | 4 |
0.110 | 139728 | 2 |
0.115 | 66632 | 2 |
Last trade - 10.10am 24/07/2024 (20 minute delay) ? |
Featured News
IMC (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online